Context sidebar

General communications

04.01.2021

COVID-19 vaccine Comirnaty from Pfizer/BioNTech: Information for healthcare professionals concerning the sixth vaccine dose

Corona vaccine Comirnaty® (BNT162b2) from Pfizer/BioNTech: up to 6 doses per vial possible

01.01.2021

Information about electronic pharmacovigilance reports

The required tools have been available for years

19.12.2020

Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland

Vaccine from Pfizer/BioNTech authorised in the rolling review procedure after close scrutiny of the risks and benefits

11.12.2020

Benefits and risks of Covid-19 vaccines: rapid authorisations are possible, but premature vaccinations are not the answer for Switzerland

The safety of the Swiss population has top priority

08.12.2020

ICMRA statement on the continuation of clinical trials

ICMRA recommends continued follow-up of study subjects in clinical trials of the SARS-CoV2 vaccine

07.12.2020

Janssen-Cilag AG applies to have its vaccine candidate authorised

Swissmedic is examining Janssen’s COVID-19 vaccine in a rolling submission procedure

07.12.2020

New reporting routes for adverse drug reaction reports by healthcare professionals from 1 January 2021

Drug safety

04.12.2020

Access Consortium statement on COVID-19 vaccines evidence

The medicines regulators within the Access Consortium will only authorise vaccines if their benefits outweigh the risks

03.12.2020

Aufsichtsabgabe 2020 – Selbstdeklaration

Eingabefrist: 22. Januar 2021

20.11.2020

Interruption of production at Swiss contract manufacturer may temporarily disrupt supplies

Swissmedic inspection uncovers Good Manufacturing Practice (GMP) deficiencies

Last modification 29.03.2020

Top of page